Hims & Hers Health, Inc. · 2025 Q4
ReportedFeb 24, 2026
Period endedDec 31, 2025
Rule of 40+30
Reported this quarter
Revenue
$618M
QoQ +3.1%
YoY +28.4%
EPS
$0.08
QoQ +33.3%
YoY -27.3%
Free Cash Flow
$12M
QoQ -85.7%
YoY -80.7%
Gross Margin
71.9%
QoQ -1.9 pp
YoY -4.9 pp
FCF Margin
1.9%
QoQ -12.0 pp
YoY -10.9 pp
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1773751.
HTML
8-K results announcement
Filed Feb 23, 2026
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
380 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
83 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2025, filed Feb 23, 2026
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure HIMS has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for 2025 Q4, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings
Coverage around this release
R40
HIMS Perfect Storm: FDA, DOJ, and Novo Nordisk Close In — Stock Down 75% From Highs
News · Feb 12, 2026
R40
HHS Refers Hims to DOJ for GLP-1 Drug Investigation
News · Feb 6, 2026
R40
HIMS Enters Cancer Diagnostics with $250 Galleri Test
News · Feb 5, 2026
R40
Hims Launches $99 GLP-1 Pill, Undercuts Novo Nordisk by 90%
News · Feb 5, 2026
News
FDA to restrict GLP-1 compounding, names Hims
FDA
News
HHS refers Hims to DOJ for GLP-1 investigation
@himshouse on X
News
Hims CFO Exercises Options and Sells Shares
Stock Titan